Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-Derived suppressor cell subpopulations in the bone marrow

Leukemia

Volumn 26, Issue 11, 2012, Pages 2424-2428

  Van Valckenborgh, E ^a   Schouppe, E ^a,b   Movahedi, K ^a,b   De Bruyne, E ^a   Menu, E ^a   De Baetselier, P ^a,b   VanDerkerken, K ^a   Van GinDerachter, J A ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW; IMMUNE DEFICIENCY; IMMUNOTHERAPY; LETTER; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 84869093412     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.113     Document Type: Letter

References (15)

1. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009; 23: 449-456.
2. Spaapen RM, Groen RW, van den OudenalDer K, Guichelaar T, van Elk M, Aarts-Riemens T et al. Eradication of medullary multiple myeloma by CD4 cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen. Clin Cancer Res 2010; 16: 5481-5488.
3. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007; 138: 563-579. (Pubitemid 47208476)
4. Frassanito MA, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol 2001; 125: 190-197. (Pubitemid 32758427)
5. Gabrilovich DI, Nagaraj S. Myeloid-Derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
6. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A et al. Identification of discrete tumor-induced myeloid-Derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233-4244.
7. Greten TF, Manns MP, Korangy F. Myeloid Derived suppressor cells in human diseases. Int Immunopharmacol 2011; 11: 802-807.
8. Asosingh K, Radl J, Van Riet I, Van Camp B, VanDerkerken K. The 5TMM series: A useful in vivo mouse model of human multiple myeloma. Hematol J 2000; 1: 351-356.
9. Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE et al. Increased level of both CD4FOXP3 regulatory T cells and CD14HLA-DR/low myeloid-Derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010; 72: 540-547.
10. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-Derived suppressor cells. J Immunol 2009; 182: 5693-5701.
11. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003; 170: 270-278. (Pubitemid 36026149)
12. Rodriguez PC, Hernandez CP, Morrow K, Sierra R, Zabaleta J, Wyczechowska DD et al. L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression. J Immunol 2010; 185: 5198-5204.
13. Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differentiation in cancer: The role of reactive oxygen species. J Leukoc Biol 2003; 74: 186-196. (Pubitemid 38040415)
14. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y et al. Expansion of myeloid immune suppressor GrCD11b cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6: 409-421. (Pubitemid 39361441)
15. Yang L, Edwards CM, Mundy GR. Gr-1CD11b myeloid-Derived suppressor cells: Formidable partners in tumor metastasis. J Bone Miner Res 2010; 25: 1701-1706.